VENLO, Netherlands & GERMANTOWN, Md., May 28, 2026
QIAGEN announced the availability of two custom-designed research-use-only (RUO) QIAcuity digital PCR assays to support infectious disease research and surveillance efforts related to the ongoing Bundibugyo ebolavirus outbreak. The assays, developed using publicly available genomic sequence data released during the outbreak response, target the virus’s nucleoprotein (NP) and VP35 regions.
Designed for use with the company’s QIAcuity digital PCR platform, the assays aim to help qualified laboratories conduct pathogen research, wastewater surveillance, environmental monitoring, and analytical evaluations. Initial in silico analysis demonstrated no mismatches with currently published outbreak sequences, supporting their potential utility in outbreak-related research activities.
Digital PCR Assays Expand Pathogen Monitoring Capabilities
The newly introduced assays are part of QIAGEN’s broader Sample to Insight portfolio and are intended to provide laboratories with adaptable molecular tools as new infectious disease threats emerge. Available through QIAGEN’s custom assay workflow on a make-to-order basis, the assays can be integrated into existing QIAcuity workflows, enabling researchers to rapidly evaluate Bundibugyo ebolavirus targets.
The company emphasized that the assays are strictly for research purposes and are not approved for diagnostic use. Their availability reflects the growing importance of flexible molecular technologies in strengthening public health preparedness and outbreak surveillance infrastructure.
Advertisement
Comprehensive Workflow Solutions Support Outbreak Research
In addition to the new digital PCR assays, QIAGEN highlighted its wider infectious disease research portfolio, which includes QIAseq next-generation sequencing panels, sample preparation technologies, and molecular workflow kits that are available for immediate delivery. These solutions support nucleic acid extraction, processing, sequencing, and downstream analysis for research applications involving emerging pathogens.
By combining digital PCR with sequencing technologies, laboratories can enhance genomic surveillance efforts and gain deeper insights into pathogen evolution, transmission dynamics, and environmental prevalence during outbreak situations.
QIAGEN Strengthens Global Public Health Research Readiness
QIAGEN stated that supporting laboratories with rapid access to molecular research technologies remains a critical part of global outbreak preparedness. The company noted that as genomic information becomes available during emerging infectious disease events, researchers require reliable tools capable of being quickly incorporated into surveillance and research programs.
According to QIAGEN, the QIAcuity platform enables sensitive nucleic acid detection and quantification across a wide range of applications, including infectious disease monitoring and environmental surveillance. The launch of the Bundibugyo ebolavirus assays reinforces the company’s commitment to helping public health organizations and research institutions strengthen response capabilities during global health emergencies.
Source:QIAGEN press release
